{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T12:29:37Z","timestamp":1722947377901},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T00:00:00Z","timestamp":1400198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0097262","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T16:33:06Z","timestamp":1400257986000},"page":"e97262","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01437241","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Gir\u00f3n-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Romero-Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"M\u00e1rquez-Solero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Martinez-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"L\u00f3pez-Ruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"de la Torre-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"T\u00e9llez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcial","family":"Delgado-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Garcia-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed O.","family":"Mohamed-Balghata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of Sociedad Andaluza de Enfermedades Infecciosas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"ref1","first-page":"4680","article-title":"TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother","volume":"48","author":"K Andries","year":"2004"},{"key":"ref2","first-page":"F49","article-title":"An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS","volume":"17","author":"BG Gazzard","year":"2003"},{"issue":"17","key":"ref3","first-page":"2487","article-title":"A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects","volume":"AIDS","author":"B Gruzdev","year":"2009"},{"key":"ref4","first-page":"2289","article-title":"Efficacy and safety of Etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS","volume":"23","author":"C Katlama","year":"2009"},{"key":"ref5","first-page":"1045","article-title":"Efficacy and safety of Etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther","volume":"15","author":"C Katlama","year":"2010"},{"key":"ref6","unstructured":"European Medicines Agency. Intelence. Product information. 2011. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/000900\/WC500034180.pdf<\/ext-link>. Accessed 2013 Feb."},{"key":"ref7","unstructured":"U.S. Food and Drug Administration. Intelence. Full prescribing information. 2011. Available: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022187s010lbl.pdf<\/ext-link>. Accessed 2013 Feb."},{"key":"ref8","first-page":"883","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (Etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med","volume":"9","author":"K Ruxrungtham","year":"2008"},{"key":"ref9","first-page":"222","article-title":"Pharmacokinetics and safety of Etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J Acquir Immune Defic Syndr","volume":"52","author":"M Boffito","year":"2009"},{"key":"ref10","first-page":"711","article-title":"Pharmacokinetics of once-daily Etravirine without and with once-daily darunavir\/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther","volume":"15","author":"E DeJesus","year":"2010"},{"key":"ref11","first-page":"681","article-title":"Intracellular and plasma pharmacokinetics of 400 mg of Etravirine once daily versus 200 mg of Etravirine twice daily in HIV-infected patients. J Antimicrob Chemother","volume":"67","author":"A Gutierrez-Valencia","year":"2012"},{"key":"ref12","first-page":"847","article-title":"Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs","volume":"72","author":"JD Croxtall","year":"2012"},{"key":"ref13","first-page":"25","article-title":"Pharmacokinetic interactions between Etravirine and non-antiretroviral drugs. Clin Pharmacokinet","volume":"50","author":"TN Kakuda","year":"2011"},{"key":"ref14","first-page":"561","article-title":"Clinical pharmacokinetics and pharmacodynamics of Etravirine. Clin Pharmacokinet","volume":"48","author":"M Scholler-Gyure","year":"2009"},{"key":"ref15","first-page":"553","article-title":"Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther","volume":"18","author":"RP van Heeswijk","year":"2013"},{"key":"ref16","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf<\/ext-link>. Accessed 2013 Feb 12."},{"key":"ref17","first-page":"2249","article-title":"Phase 2 double-blind, randomised trial of Etravirine versus efavirenz in treatment-naive patients: 48 week results. AIDS","volume":"25","author":"B Gazzard","year":"2011"},{"key":"ref18","first-page":"65","article-title":"A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to Etravirine. AIDS","volume":"25","author":"L Waters","year":"2011"},{"key":"ref19","first-page":"1","article-title":"Lipid-lowering effect and efficacy after switching to Etravirine in HIV-infected patients with intolerance to suppressive HAART. HIV Clin Trials","volume":"14","author":"JL Casado","year":"2013"},{"key":"ref20","first-page":"141","article-title":"Is Etravirine and two nucleosides an option for HIV with an isolated K103N mutation?. AIDS","volume":"27","author":"M Estebanez","year":"2013"},{"key":"ref21","unstructured":"HIV Drug Resistance Database. Standford University (2013) Available at: http:\/\/hivdb.stanford.edu\/<\/ext-link>."},{"key":"ref22","first-page":"503","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS","volume":"24","author":"J Vingerhoets","year":"2010"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0097262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:20:47Z","timestamp":1540218047000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0097262"}},"subtitle":[],"editor":[{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0097262","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2014,5,16]]}}}